Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2

Loading news article.

Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2 | WAPE

Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2

Article summary

Related companies

Comments —